With the shares rallying, let's check how the charts are doing.
The technical history of the stock is limited but buyers appear more aggressive than sellers.
I have no patience moving forward with a large firm standing on a sloppy book, trying to digest an acquisition it needs to make, but can only questionably afford.
The charts for this drug developer are starting to take shape.
Finding 'off the radar' names that can deliver solid earnings and revenue growth will be key to managing one's growth portfolio.
These recently downgraded names are displaying both quantitative and technical deterioration.
Also, I really like the idea of owning the shares - you have time - prior to the split into two firms.
There are reasons to be optimistic about Hims & Hers Health and OptiNose Inc.
It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.
A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.